局部溴莫尼定预防抗VEGF玻璃体腔注射后眼压骤升的随机交叉试验
这项随机交叉试验纳入58只非青光眼眼(55例患者,116次访视),比较注射前20分钟使用0.15%酒石酸溴莫尼定与不予预防对玻璃体腔注射抗VEGF药物后眼压骤升的影响。结果显示预防组在注射后即刻、10分钟和20分钟的眼压均更低,眼压较注射前升高>20 mmHg及即刻眼压>50 mmHg的比例也更小。
要点
- 注射前20分钟使用0.15%酒石酸溴莫尼定可降低抗VEGF注射后即刻、10分钟和20分钟的眼压。
- 预防组眼压较注射前升高>20 mmHg及即刻眼压>50 mmHg的比例均低于无预防组。
- 无预防时2只眼即刻眼压>70 mmHg并接受了前房穿刺。
核心结论
- 局部酒石酸溴莫尼定预防可有效减少非青光眼眼抗VEGF玻璃体腔注射后的眼压骤升。
- 该预防措施可能容易融入眼科医生的现有实践。
研究设计与样本
- 随机交叉试验,纳入2016年12月至2017年7月连续接受玻璃体腔抗VEGF注射的非青光眼眼。
- 所有眼随机分配至无预防或注射前20分钟使用0.15%酒石酸溴莫尼定,在两次连续访视中交叉。
- 共58只眼(55例患者,116次访视),平均(SD)年龄74.3(11.6)岁,62%为女性。
主要发现
- 平均基线眼压为15.3(2.3)mmHg(范围11-20)。
- 无预防访视时注射后即刻平均眼压为41.6(12)mmHg(范围17-81)。
- 与无预防相比,预防访视在T0(p<0.001)、T10(p=0.001)和T20(p=0.043)的眼压更低。
- 预防访视眼压较注射前升高>20 mmHg的比例更小(p=0.002),T0眼压>50 mmHg的比例更小(p=0.036)。
- 无预防时2只眼(2例患者)在T0眼压>70 mmHg,接受了前房穿刺。
关键数值与推荐
- 预防方案为注射前20分钟使用0.15%酒石酸溴莫尼定。
- 眼压测量时间点为注射后即刻(T0)、10分钟(T10)和20分钟(T20)。
临床怎么用
- 对接受玻璃体腔抗VEGF注射的非青光眼眼,可考虑注射前20分钟使用0.15%酒石酸溴莫尼定以减轻眼压骤升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the effect of topical brimonidine tartrate prophylaxis on intraocular pressure (IOP) spikes following intravitreal injection of antivascular endothelial growth factor (anti-VEGF) agents. METHODS: This is a randomised crossover trial of consecutive non-glaucomatous eyes receiving intravitreal anti-VEGF injections between December 2016 and July 2017. All eyes were randomly assigned to no prophylaxis or topical brimonidine tartrate 0.15 % administered 20 min prior to injection in one of two consecutive visits. Measurements of IOP were obtained immediately (T0), 10 min (T10) and 20 min (T20) after injection during the visits with and without prophylaxis. RESULTS: Among the 58 eyes of 55 patients (116 visits), the mean (SD) age was 74.3 (11.6), and 62% were female. The mean baseline IOP was 15.3 (2.3) mm Hg (range: 11-20). On average, the immediate postinjection IOP during the visit without prophylaxis was 41.6 (12) mm Hg (range: 17-81). Compared with no prophylaxis, the visit with preadministered topical brimonidine tartrate had a lower IOP at T0 (p<0.001), T10 (p=0.001) and T20 (p=0.043), and a smaller proportion of eyes with IOP elevation of greater than 20 mm Hg from preinjection (p=0.002) and IOP greater than 50 mm Hg at T0 (p=0.036). Without prophylaxis, two eyes (two patients) had an IOP of greater than 70 mm Hg at T0 and thus underwent anterior chamber paracentesis. CONCLUSION: Topical brimonidine tartrate prophylaxis for intravitreal injection of anti-VEGF agents effectively reduces IOP spikes in non-glaucomatous eyes and may be easily incorporated into ophthalmologists' current practice. TRIAL REGISTRATION NUMBER: NCT03513172.
引用
- Felfeli T, Hostovsky A, Trussart R, et al. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol. 2018. PMID: 30573499. doi:10.1136/bjophthalmol-2018-312603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。